Tapewire

Nasdaq · USD

COLL

COLLEGIUM PHARMACEUTICAL, INC

Export transactions ↓
Tapewire entity
5169
SEC CIK
0001267565
Parsed reports
359

Last 12 months

Inside the activity.

0 purchase rows · 14 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202503
Dec 202503
Jan 202600
Feb 202600
Mar 202604
Apr 202600
May 202604
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 10, 2025 Filed Feb 12, 2025 16:09 UTC
Kuhlmann Shirley R.EVP and General Counsel
GrantCommon Stock 29,030 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,179

F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 29,030 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 16:09 UTC
Kuhlmann Shirley R.EVP and General Counsel
GrantCommon Stock 40,965 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,149

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC GrantCommon Stock 4,820 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002181 · form4.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,328

F1 · shares: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Smith Thomas BEVP and Chief Medical Officer
Tax withholdingCommon Stock 4,399 $30.52 $134,257.48
Disclosure

SEC source: 0001062993-25-002180 · form4.xml · nonDerivative · entry 4

Smith Thomas B · CIK 0001748462 · EVP and Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,742

F5 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Smith Thomas BEVP and Chief Medical Officer
Tax withholdingCommon Stock 1,498 $30.52 $45,718.96
Disclosure

SEC source: 0001062993-25-002180 · form4.xml · nonDerivative · entry 3

Smith Thomas B · CIK 0001748462 · EVP and Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,141

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Smith Thomas BEVP and Chief Medical Officer
GrantCommon Stock 5,313 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002180 · form4.xml · nonDerivative · entry 2

Smith Thomas B · CIK 0001748462 · EVP and Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,639

F3 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 5,313 performance share units ("PSUs") granted in the Issuer's prior fiscal year.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Smith Thomas BEVP and Chief Medical Officer
GrantCommon Stock 33,762 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002180 · form4.xml · nonDerivative · entry 1

Smith Thomas B · CIK 0001748462 · EVP and Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,326

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

F2 · balance_after: Includes 373 and 375 shares acquired on July 19, 2024 and January 17, 2025, respectively, under the Issuer's employee stock purchase plan.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Dreyer ScottEVP & Chief Commercial Officer
Tax withholdingCommon Stock 21,670 $30.52 $661,368.40
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,706

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Dreyer ScottEVP & Chief Commercial Officer
Tax withholdingCommon Stock 7,953 $30.52 $242,725.56
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,376

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Dreyer ScottEVP & Chief Commercial Officer
GrantCommon Stock 26,411 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,329

F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 26,411 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC
Dreyer ScottEVP & Chief Commercial Officer
GrantCommon Stock 45,016 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,918

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
February 04, 2025 Filed Feb 5, 2025 22:30 UTC
Lurker NancyDirector
GrantCommon Stock 12,726 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-001754 · form4.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,726

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on February 4, 2026, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on such date in shares of the Issuer's common stock.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC
Kuhlmann Shirley R.EVP and General Counsel
Exercise / conversionStock Option (Right to Purchase) · Derivative 27,500 $0.00 Strike: $21.34 $0.00
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · derivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,500 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 6,100 $33.64 $205,220.47
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,184

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.42 to $33.41, inclusive.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 21,400 $32.87 $703,407.30
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,284

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.43 to $33.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC
Kuhlmann Shirley R.EVP and General Counsel
Exercise / conversionCommon Stock 27,500 $21.34 $586,850.00
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

Read SEC document
November 12, 2024 Filed Nov 14, 2024 21:50 UTC
Karnani VikramDirector · President and CEO
GrantStock Option (Right to Purchase) · Derivative 130,344 $0.00 Strike: $31.41 $0.00
Disclosure

SEC source: 0001062993-24-019165 · form4.xml · derivative · entry 2

Karnani Vikram · CIK 0001699488 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,344

Underlying: Common Stock · 130,344 shares

Expires 2034-11-12

F2 · derivative.exercise_date: Twenty-five percent (25%) of the option shall vest and become exercisable on November 12, 2025, with the balance vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer.

Read SEC document
November 12, 2024 Filed Nov 14, 2024 21:50 UTC
Karnani VikramDirector · President and CEO
GrantCommon Stock 105,972 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-019165 · form4.xml · nonDerivative · entry 1

Karnani Vikram · CIK 0001699488 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,972

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on November 12, 2025, with the balance vesting in three annual installments thereafter, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:32 UTC
Smith Thomas BEVP and Chief Medical Officer
SaleCommon Stock 9,593 $36.62 $351,319.64
Disclosure

SEC source: 0001062993-24-016699 · form4.xml · nonDerivative · entry 1

Smith Thomas B · CIK 0001748462 · EVP and Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,816

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.56 to $36.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 06, 2024 Filed Sep 6, 2024 17:52 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 977 $37.46 $36,594.12
Disclosure

SEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,184

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.455 to $37.4592, inclusive.

Read SEC document
September 05, 2024 Filed Sep 6, 2024 17:52 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 2,400 $39.14 $93,941.04
Disclosure

SEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,161

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.01 to $39.20, inclusive.

Read SEC document
September 05, 2024 Filed Sep 6, 2024 17:52 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 16,848 $38.18 $643,256.64
Disclosure

SEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,561

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

Read SEC document
June 03, 2024 Filed Jun 5, 2024 16:06 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 700 $33.22 $23,254.00
Disclosure

SEC source: 0001062993-24-011979 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,409

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.19 to $33.31, inclusive.

Read SEC document
June 03, 2024 Filed Jun 5, 2024 16:06 UTC
Kuhlmann Shirley R.EVP and General Counsel
SaleCommon Stock 24,300 $32.55 $790,926.12
Disclosure

SEC source: 0001062993-24-011979 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,109

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.18 to $33.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
May 28, 2024 Filed May 29, 2024 16:29 UTC
Tupper ColleenEVP & Chief Financial Officer
SaleCommon Stock 19,710 $34.21 $674,367.80
Disclosure

SEC source: 0001062993-24-011413 · form4.xml · nonDerivative · entry 1

Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,845

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.94 to $34.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).

Read SEC document
May 24, 2024 Filed May 28, 2024 20:22 UTC
Dreyer ScottEVP & Chief Commercial Officer
Exercise / conversionStock Option (Right to Purchase) · Derivative 23,791 $0.00 Strike: $24.03 $0.00
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · derivative · entry 6

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,791 shares

Expires 2028-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
May 24, 2024 Filed May 28, 2024 20:22 UTC
Dreyer ScottEVP & Chief Commercial Officer
SaleCommon Stock 56,807 $33.98 $1,930,455.24
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,902

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.68 to $34.25, inclusive.

Read SEC document
May 24, 2024 Filed May 28, 2024 20:22 UTC
Dreyer ScottEVP & Chief Commercial Officer
Exercise / conversionCommon Stock 23,791 $24.03 $571,697.73
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:22 UTC
Dreyer ScottEVP & Chief Commercial Officer
Exercise / conversionStock Option (Right to Purchase) · Derivative 51,209 $0.00 Strike: $24.03 $0.00
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · derivative · entry 5

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,791

Underlying: Common Stock · 51,209 shares

Expires 2028-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:22 UTC
Dreyer ScottEVP & Chief Commercial Officer
SaleCommon Stock 51,209 $33.82 $1,732,093.22
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,918

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.36 to $34.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:22 UTC
Dreyer ScottEVP & Chief Commercial Officer
Exercise / conversionCommon Stock 51,209 $24.03 $1,230,552.27
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:21 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010537 · form4.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,508

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:22 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010540 · form4.xml · nonDerivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,468

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:23 UTC
SANTINI GINODirector
GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010543 · form4.xml · nonDerivative · entry 1

SANTINI GINO · CIK 0001276038 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,656

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:23 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010542 · form4.xml · nonDerivative · entry 1

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,468

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:23 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010541 · form4.xml · nonDerivative · entry 1

McFarlane Neil F. · CIK 0001681098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,365

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:22 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010539 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,843

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:22 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010538 · form4.xml · nonDerivative · entry 1

Balice-Gordon Rita J. · CIK 0001825625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,488

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:20 UTC GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010536 · form4.xml · nonDerivative · entry 3

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,468

F2 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 14, 2024 Filed May 16, 2024 23:20 UTC Exercise / conversionStock Option (Right to Purchase) · Derivative 28,985 $0.00 Strike: $5.73 $0.00
Disclosure

SEC source: 0001062993-24-010536 · form4.xml · derivative · entry 4

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,985 shares

Expires 2025-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
May 14, 2024 Filed May 16, 2024 23:20 UTC SaleCommon Stock 28,985 $32.30 $936,311.15
Disclosure

SEC source: 0001062993-24-010536 · form4.xml · nonDerivative · entry 2

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,775

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 14, 2024 Filed May 16, 2024 23:20 UTC Exercise / conversionCommon Stock 28,985 $5.73 $166,084.05
Disclosure

SEC source: 0001062993-24-010536 · form4.xml · nonDerivative · entry 1

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 21:26 UTC
Smith Thomas BEVP and Chief Medical Officer
SaleCommon Stock 995 $36.76 $36,580.18
Disclosure

SEC source: 0001062993-24-005212 · form4.xml · nonDerivative · entry 1

Smith Thomas B · CIK 0001748462 · EVP and Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,409

Read SEC document
February 26, 2024 Filed Feb 28, 2024 21:14 UTC
Dreyer ScottEVP & Chief Commercial Officer
SaleCommon Stock 664 $37.15 $24,669.59
Disclosure

SEC source: 0001062993-24-004754 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,918

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.01 to $37.50, inclusive.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 21:14 UTC
Dreyer ScottEVP & Chief Commercial Officer
SaleCommon Stock 9,336 $36.38 $339,600.73
Disclosure

SEC source: 0001062993-24-004754 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,582

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.96 to $36.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:15 UTC
Tupper ColleenEVP & Chief Financial Officer
Tax withholdingCommon Stock 9,453 $33.70 $318,566.10
Disclosure

SEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 4

Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,555

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:15 UTC
Tupper ColleenEVP & Chief Financial Officer
Tax withholdingCommon Stock 16,868 $33.70 $568,451.60
Disclosure

SEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 3

Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,008

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:15 UTC
Tupper ColleenEVP & Chief Financial Officer
GrantCommon Stock 30,856 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 2

Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,876

F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 30,856 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:15 UTC
Tupper ColleenEVP & Chief Financial Officer
GrantCommon Stock 40,600 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 1

Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,020

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:14 UTC
Kuhlmann Shirley R.EVP and General Counsel
Tax withholdingCommon Stock 10,610 $33.70 $357,557.00
Disclosure

SEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,409

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.